Lyell Immunopharma, Inc.
LYEL
$13.95
$0.211.53%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -248.48M | -246.41M | -274.45M | -325.66M | -331.40M |
| Total Depreciation and Amortization | 9.52M | 10.43M | 11.54M | 14.17M | 16.28M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 99.86M | 103.60M | 122.78M | 157.01M | 152.99M |
| Change in Net Operating Assets | 5.84M | -1.42M | -9.89M | -10.53M | -9.36M |
| Cash from Operations | -133.26M | -133.80M | -150.02M | -165.02M | -171.48M |
| Capital Expenditure | -711.00K | -623.00K | -780.00K | -520.00K | -517.00K |
| Sale of Property, Plant, and Equipment | 292.00K | 287.00K | 287.00K | 263.00K | -- |
| Cash Acquisitions | -41.20M | -41.20M | -41.20M | -31.35M | -31.35M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 46.59M | 43.54M | 95.79M | 170.57M | 169.40M |
| Cash from Investing | 4.98M | 2.01M | 54.10M | 138.97M | 137.54M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 102.47M | 102.13M | 50.41M | 50.62M | 621.00K |
| Repurchase of Common Stock | -1.00K | -1.00K | -1.00K | 0.00 | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -1.00K | 0.00 | 0.00 | 0.00 |
| Cash from Financing | 102.47M | 102.13M | 50.41M | 50.62M | 621.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -25.82M | -29.66M | -45.52M | 24.57M | -33.32M |